je.st
news
Tag: early
Start planning early to beat the grasshoppers this year
2015-04-06 20:13:00| Beef
By Heather Smith Thomas Controlling grasshoppers and Mormon crickets takes a watchful and considered approach. Here are tips from pasture experts. read more
Tags: year
start
early
planning
Met Coal Market Will Make A Turnaround In Long Term, But Early 2015 To Remain Challenging
2015-03-29 13:39:07| Industrial Machines - Topix.net
Met coal market fundamentals have been adversely affected by weak economic conditions and a strong U.S. Dollar, which have resulted in excess met coal supply. As the met coal market remains oversupplied, met coal prices have been adversely affected; recently, the 2Q'15 met coal benchmark price settled at a new six-year low of $109.5 per ton.
UK Pork Trading Slow in Early 2015
2015-03-27 01:00:00| ThePigSite - Industry News
UK - According to data from HMRC, both UK imports and exports of pork in January 2015 were lower than a year earlier.
Early adopter: Microsofts Windows 10 will support up to 8K displays
2015-03-24 21:00:35| Extremetech
Windows 10 will treat 4K as a first class citizen and plans to support 8K, despite that standard being years from common. Is Microsoft hedging its bets, or planning a fast resolution transition?
Tags: support
windows
early
displays
Mercks Pivotal KEYNOTE-006 Study in First-Line Treatment for Advanced Melanoma Met Co-Primary Endpoints and Will be Stopped Early
2015-03-24 13:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Demonstrated Superior Overall Survival and Progression-Free Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the randomized, pivotal Phase 3 study (KEYNOTE-006) investigating KEYTRUDA (pembrolizumab) compared to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary endpoints of progression-free survival and overall survival. The trial will be stopped early based on the recommendation of the studys independent Data Monitoring Committee. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] next »